Clinical Trials Logo

Filter by:
NCT ID: NCT06139055 Active, not recruiting - Healthy Volunteers Clinical Trials

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Start date: October 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.

NCT ID: NCT06136897 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Start date: March 13, 2017
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial tests how well trastuzumab and pertuzumab work in treating patients with HER2-amplified non-breast, non-gastric/gastroesophageal junction, and non-colorectal cancers. Pertuzumab and trastuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When pertuzumab or trastuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Trastuzumab is approved for the treatment of certain types of HER2-amplified cancers such as breast and gastric cancers. Research has shown that treatment with two anti-HER2 therapies in combination may be more effective at treating HER2-positive patients than giving one anti-HER2 therapy alone. Giving trastuzumab and pertuzumab in combination may be effective at treating patients with HER2-amplified cancers that aren't breast, gastric, or colorectal.

NCT ID: NCT06134804 Active, not recruiting - Clinical trials for Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

Engage
Start date: October 24, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody response against each of the 4 influenza vaccine strains, as compared to HD QIV given alone and further show that ExPEC9V given together with HD QIV does not induce lower antibody response against each of the vaccine O-serotype antigens, as compared to ExPEC9V given alone.

NCT ID: NCT06133816 Active, not recruiting - Lung Cancer Clinical Trials

Lung Cancer Screening Eligibility Assessment

Start date: July 31, 2023
Phase: N/A
Study type: Interventional

The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.

NCT ID: NCT06133049 Active, not recruiting - Multiple Sclerosis Clinical Trials

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

Start date: March 16, 2021
Phase:
Study type: Observational

The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with multiple sclerosis (MS) who were exposed to ozanimod during pregnancy; the second is women with MS exposed to select other disease-modifying therapies (DMTs) during pregnancy; the third is women with MS not exposed to any DMTs during pregnancy. This study will use data from a large US healthcare claims database.

NCT ID: NCT06131944 Active, not recruiting - Sleep Clinical Trials

A Combined School- and Home-Based Sleep Promotion Program

Start date: March 26, 2024
Phase: N/A
Study type: Interventional

The goal of this single group trial is to test the feasibility and acceptability of a combined school- and home-based sleep promotion program for young children prior to the kindergarten transition.

NCT ID: NCT06130904 Active, not recruiting - Opioid Prescribing Clinical Trials

Effect of Academic Detailing on Opioid Prescribing by Dentists to Adolescents and Young Adults

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

This randomized controlled trial will test whether an academic detailing educational outreach intervention (referred to as "academic detailing" throughout) decreases opioid prescribing to patients aged 13-30 years among high-prescribing dentists in Southeast Michigan. The primary objective is to evaluate whether an academic detailing intervention reduces the number of dispensed opioid prescriptions to patients aged 13-30 years.

NCT ID: NCT06130722 Active, not recruiting - Clinical trials for Locally Advanced/Metastatic Solid Tumors

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Start date: October 30, 2023
Phase: Phase 1
Study type: Interventional

First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies, including immune check-point inhibitors administered in single-agent or combination use.

NCT ID: NCT06130345 Active, not recruiting - SARS-CoV-2 Clinical Trials

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

Start date: April 14, 2023
Phase:
Study type: Observational

The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.

NCT ID: NCT06127147 Active, not recruiting - Clinical trials for Coronary Artery Bypass Graft

High-intensity Inspiratory Muscle Training as a Pre-cardiac Rehabilitation in Heart Disease

Start date: December 20, 2023
Phase: N/A
Study type: Interventional

Background/aim: Endothelial function is closely associated with coronary artery health among individuals being treated for heart disease. An impairment in endothelial function promotes arterial stiffening that directly contributes to elevated systolic blood pressure as a result of increased vascular resistance. Inspiratory muscle training is simply a form of training consisting of repeated inspirations against resistance. Inspiratory muscle training has also been applied to patients with chronic disease or as an additional therapy for cardiac rehabilitation and it has proven to be safe in these groups. Few studies in the literature examined the effects of high-intensity inspiratory muscle training in this population, however, these studies did not examine the direct effects of inspiratory muscle training on vascular function. To the best of our knowledge, the effects of inspiratory muscle training in patients with heart disease on endothelial function and arterial stiffness prior to starting cardiac rehabilitation have not been investigated. This study aims to investigate and interpret whether high-intensity inspiratory muscle training, beyond the usual care of heart disease, improves endothelial function and arterial stiffness. Methods: The study was designed as a randomized controlled trial. Patients will be allocated for inspiratory muscle training (IMT) with 60% of maximum inspiratory pressure (MIP) or sham inspiratory muscle training (Sham-control), for 4 weeks. In both groups, before and after 4-week training, cardiovascular functions will be measured and compared.